Latest Personalised Supplements News

Elixinol Wellness lifted Q3 gross profit 27% and delivered a fourth consecutive quarter of positive underlying operating cash flow, despite statutory operating cash flow remaining negative and cash below A$1 million. The proposed all-scrip Vitable acquisition could add scale, but shareholder approval and a thin liquidity buffer remain important next tests.

Elixinol Wellness will acquire personalised supplement platform Vitable for headline consideration of A$2.5 million in shares, adding recurring revenue and more than 7,850 active subscribers. The deal could lift combined revenue to A$27 million by 2028, but remains subject to shareholder approval and carries meaningful dilution risk.